News

Comera Life Sciences to Present Topline Results of SEQURUS-2 Study at 14th Annual Bioprocessing Summit

WOBURN, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life…

2 years ago

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including…

2 years ago

Enzo Biochem to Launch Monkeypox Testing Services this Week

NEW YORK, NY, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading…

2 years ago

LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18

LONDON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it…

2 years ago

Surrozen Reports Second Quarter 2022 Financial Results

Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoingPreclinical proof-of-concept data for multiple programs presented and published in…

2 years ago

RAPT Therapeutics Reports Second Quarter 2022 Financial Results

Company maintains strong cash position of $207.3 millionSOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc.…

2 years ago

OrthoPediatrics Corp. Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

WARSAW, Ind., Aug. 11, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively…

2 years ago

Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement

FORT LAUDERDALE, Fla., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a…

2 years ago

Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis

-- PAS002 is a proprietary DNA tolerizing vaccine construct encoding GlialCAM ---- PAS002 effectively reduces disease severity, delays onset of…

2 years ago